How intratumor heterogeneity can surpass therapeutic resistance

What is it about?

Intratumor heterogeneity with multiregion NGS analysis in a short-term approach and single-cell genome-NGS technological system in longterm perspective can be used as biomarker to predict tumor responsiveness and guide comprehensive primary systemic treatment. However, this ITH concept alone or coupled with repeated ctDNA-NGS genome system to identify spatiotemporal evolution of intrapatient heterogeneity will require large-scale translational research studies for confirmation before these innovative biomarkers could be evaluated in clinical trials.

Featured Image

Why is it important?

Future biomarkers and therapeutic targets

Perspectives